A Firsthand Look at the ExtendMed Advantage
With a wide range of promotional and CME programs, ExtendMed has become a leading name in medical education. Here you can access a sampling of our recent programs. Please note that the programs marked CME are complete, fully-accredited courses available for medical certification.
SCOPE of Pain: Safe and Competent Opioid Prescribing Education
18816 registrants. 11133 have completed the program.
SCOPE of pain is an educational program that will help you safely and competently manage your patients with chronic pain. Through the case of Mary Williams, a 42 year old with painful diabetic neuropathy and chronic low back pain, you'll learn how to: 1) decide on appropriateness of opioid analgesics; 2) assess for opioid misuse risk; 3) counsel patients about opioid safety, risks and benefits; 4) competently monitor patients prescribed opioids for benefit and harm; 5) make decisions on continuing or discontinuing opioid analgesics; 6) safely discontinue opioids when there is too little benefit or too much risk and harm. Offered in collaboration with the Council of Medical Specialty Societies (CMSS) and the Federation of State Medical Boards (FSMB), this program addresses the FDA mandate to manufacturers of extended release/long-acting (ER/LA) opioid analgesics, by providing comprehensive prescriber education in the safe use of these medications. It also addresses many key elements of the physician education component of the Obama Administration's prescription drug abuse prevention plan on prescriber education released in April 2011. This program is funded by an unrestricted educational grant awarded by the manufacturers of ER/LA opioid analgesics, known as the REMS Program Companies (RPC).
Clinical Updates in Anticoagulation Therapy for Stroke Prevention
254 registrants. 89 have completed the program.
Through a free-form faculty discussion you will learn about the most up-to-date treatments in anticoagulation therapy for preventing stroke in patients with atrial fibrillation. Our expert faculty panel discusses a selection of the most important issues today including guidelines, bleeding risk, renal issues, the role of aspirin, current and new anticoagulants and perioperative management.This online continuing education program is brought to you by the Anticoagulation Forum and Boston University School of Medicine's Department of Continuing Medical Education.
Update on the Treatment Options for Opioid-Induced Constipation
The majority of patients treated with opioid therapy for cancer and non-cancer pain experience opioid-induced constipation (OIC). OIC is a common and debilitating adverse event associated with chronic opioid therapy that is associated with a substantial clinical and economic burden. This condition is not trivial as it affects the patient's quality of life and can lead them to reduce, discontinue or change effective analgesic therapy. While commonly used over-the-counter stool softeners and laxatives are generally effective; they do not address the underlying pathophysiological mechanism by which opioids cause OIC. Research advances have improved the understanding of those underlying mechanisms and have resulted in the identification of new pharmacologic agents that target the μ-opioid receptor interaction while maintaining the analgesic benefit of the opioid and minimizing the risk of withdrawal. This webcast is the second activity in a 3-module series that reviews current and evolving approaches to managing OIC.
Influenza and Chronic Medical Conditions: How Risk Adds to Risk in the Older Adult
256 registrants. 38 have completed the program.
This educational webcast explores ways in which influenza and comorbidities such as heart disease, lung disease, and diabetes interact to dramatically increase the risks of influenza-related complications, hospitalization, and death. This non-CME presentation also stresses how important it is for health care providers to identify and immunize patients at high risk of influenza, especially older adults who are likely to have one or more comorbid conditions. Lastly, the program reviews why the use of vaccines that generate a higher immune response may be important to help prevent influenza infection and its potentially life-threatening complications in older adults. Influenza and Chronic Medical Conditions: How Risk Adds to Risk in the Older Adult is now available on demand through April 2015.
Quadrivalent Vaccine: The Next Step Forward in Influenza Immunization
341 registrants. 52 have completed the program.
This webcast, focusing on the information needs of primary-care clinicians, will feature 2 presentations. Robert B. Belshe, MD, Professor in the Department of Internal Medicine, Division of Infectious Diseases, Allergy and Immunology at St. Louis University, will discuss the impact of influenza on the population, the importance of having quadrivalent vaccines, and the role of clinicians in serving as vaccine advocates for their patients. He will also share pertinent safety and efficacy data on a quadrivalent influenza vaccine approved for use in persons 6 months of age and older. The second talk will offer guidance on proper coding for quadrivalent influenza vaccines and key reimbursement issues. The presenter is LaDonna K. Johnson, Managing Consultant with Medical Revenue Solutions, LLC, in Grain Valley, MO.
Fluzone®Intradermal Quadrivalent (Influenza Vaccine): An Option for the Busy Influenza Season
33 registrants. 1 have completed the program.
For the first time, an influenza vaccine injected into the skin through a microneedle will be available in a quadrivalent formulation with 2 influenza A viruses and 2 influenza B viruses for the 2015-2016 influenza season. This non-CME webcast will share key safety and immunogenicity data on the new formulation, discuss best practices for implementing its use, and offer practical tips on how medical offices, clinics, and other vaccination sites can manage the often-hectic influenza season with equal measures of planning, execution, and education. Intradermal influenza vaccine is an immunization option for adults 18 through 64 years of age. The device includes a prefilled, single-use syringe, affixed microneedle, and integrated needle shield an all-in-1 device that eliminates steps in the influenza immunization administration process.